Literature DB >> 8901651

Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities.

I Juhan-Vague1, S D Pyke, M C Alessi, J Jespersen, F Haverkate, S G Thompson.   

Abstract

BACKGROUND: Disturbances of the fibrinolytic system that lead to decreased removal of fibrin deposits may be important risk factors for coronary thrombosis. There is as yet no consensus on the prognostic value of fibrinolytic parameters, which may be attributed in part to the choice of confounding variables controlled for. METHODS AND
RESULTS: The ECAT study is a prospective multicenter study of 3043 patients with angina pectoris followed for 2 years. Baseline measurements included 10 fibrinolytic variables. The results were analyzed in relation to the subsequent incidence of myocardial infarction or sudden coronary death. They are presented before and after adjustment for clusters of confounding variables that are markers of different mechanisms: insulin resistance (body mass index, triglyceride, and HDL cholesterol), inflammation (fibrinogen and C-reactive protein), and endothelial cell damage (von Willebrand factor). An increased incidence of events was associated with higher baseline concentrations of tissue plasminogen activator (TPA) antigen (P = .0002), plasminogen activator inhibitor-1 (PAI-1) activity (P = .02), and PAI-1 antigen (P = .001). The associations of PAI-1 activity and PAI-1 antigen with risk of events disappeared after adjustment for parameters reflecting insulin resistance but were not affected by other adjustments. TPA antigen was affected to a similar extent by adjustment for parameters reflecting insulin resistance. Inflammation, or endothelial cell damage, but the risk association disappeared only after combined adjustments.
CONCLUSIONS: The prognostic role of PAI-1 in predicting coronary events is related principally to insulin resistance, whereas that of TPA antigen could be explained only by its relationship with different mechanisms, including insulin resistance, inflammation and endothelial cell damage.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901651     DOI: 10.1161/01.cir.94.9.2057

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  53 in total

1.  Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study.

Authors:  L Maria Belalcazar; Christie M Ballantyne; Wei Lang; Steven M Haffner; Julia Rushing; Dawn C Schwenke; F Xavier Pi-Sunyer; Russell P Tracy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-21       Impact factor: 8.311

2.  Evaluation of overall fibrinolytic activity in patients with coronary artery ectasia: global fibrinolytic capacity.

Authors:  Abdullah Dogan; Bahattin Tunc; Oktay Ergene; Mehmet Ozaydin; Cem Nazli; Ahmet Altinbas; Omer Gedikli
Journal:  Int J Cardiovasc Imaging       Date:  2003-12       Impact factor: 2.357

Review 3.  Cardiovascular risks in obesity.

Authors:  E C Uchegbu; P G Kopelman
Journal:  J Endocrinol Invest       Date:  2002-11       Impact factor: 4.256

4.  Biochemical and morphological alterations in lungs induced by experimental inhibition of fibrinolytic activity.

Authors:  Izzet Hoşgör; Aysen Yarat; Nukhet Tüzüner; Faruk Alkan; Nesrin Emekli; Sarfraz Ahmad
Journal:  Mol Cell Biochem       Date:  2002-12       Impact factor: 3.396

5.  The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials.

Authors:  Penny M Kris-Etherton; Paul W Stewart; Henry N Ginsberg; Russell P Tracy; Michael Lefevre; Patricia J Elmer; Lars Berglund; Abby G Ershow; Thomas A Pearson; Rajasekhar Ramakrishnan; Stephen F Holleran; Barbara H Dennis; Catherine M Champagne; Wahida Karmally
Journal:  J Nutr       Date:  2020-08-01       Impact factor: 4.798

Review 6.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

Review 7.  Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.

Authors:  Victoria A Ploplis
Journal:  Curr Drug Targets       Date:  2011-11       Impact factor: 3.465

8.  Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population.

Authors:  J A Schoenhard; F W Asselbergs; K A Poku; S A Stocki; S Gordon; D E Vaughan; N J Brown; J H Moore; Scott M Williams
Journal:  Hum Genet       Date:  2008-10-25       Impact factor: 4.132

9.  Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.

Authors:  Matteo Cesari; Stephen B Kritchevsky; Hal H Atkinson; Brenda W Penninx; Mauro Di Bari; Russell P Tracy; Marco Pahor
Journal:  Am Heart J       Date:  2009-02       Impact factor: 4.749

10.  Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy.

Authors:  Antonio Barbato; Roberto Iacone; Giovanni Tarantino; Ornella Russo; Paolo Sorrentino; Sonia Avallone; Ferruccio Galletti; Eduardo Farinaro; Elisabetta Della Valle; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2009-04-07       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.